Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference

Leap Therapeutics (Nasdaq: LPTX), a biotech company specializing in targeted and immuno-oncology therapeutics, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference in New York.

Rhea-AI Summary

Leap Therapeutics (Nasdaq: LPTX), a biotech company specializing in targeted and immuno-oncology therapeutics, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference in New York. Douglas E. Onsi, President and CEO, will engage in a fireside chat scheduled for Wednesday, December 4, 2024, at 4:00 p.m. Eastern Time. The presentation will be accessible via live webcast on the company's investor relations website, with a replay available for time viewing.

Argus Session date unavailable

+5.16% session move Open Argus

Details

News Market Reaction – LPTX

The recorded move for LPTX in the trading session of this news was +5.16%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Nov. 26, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 36^th Annual Healthcare Conference in New York, NY.

Leap Presentation Details:

Piper Sandler 36^th Annual Healthcare Conference
Date: Wednesday, December 4, 2024
Time: 4:00 p.m. Eastern Time

A live webcast of the fireside chat may be accessed on the Investors page of the company's website at https://investors.leaptx.com/, where a replay of the events will also be available for a limited time.

About Leap Therapeutics
Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being developed in patients with esophagogastric, colorectal, and gynecological cancers. Leap's pipeline also includes FL-501, a humanized monoclonal antibody targeting the growth and differentiation factor 15 (GDF-15) protein, in preclinical development. For more information about Leap Therapeutics, visit http://www.leaptx.com or view our public filings with the SEC that are available via EDGAR at http://www.sec.gov or via https://investors.leaptx.com/.

CONTACT:

Douglas E. Onsi
President & Chief Executive Officer
Leap Therapeutics, Inc.
617-714-0360
donsi@leaptx.com

Matthew DeYoung
Investor Relations
Argot Partners
212-600-1902
leap@argotpartners.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/leap-therapeutics-to-participate-at-piper-sandler-36th-annual-healthcare-conference-302313181.html

SOURCE Leap Therapeutics, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Leap Therapeutics (LPTX) presenting at the Piper Sandler Healthcare Conference 2024?

Leap Therapeutics (LPTX) is presenting on Wednesday, December 4, 2024, at 4:00 p.m. Eastern Time.

How can I watch Leap Therapeutics' (LPTX) presentation at the Piper Sandler Conference?

The presentation can be watched via live webcast on Leap Therapeutics' investor relations website at https://investors.leaptx.com/, where a replay will also be available.

What type of presentation will Leap Therapeutics (LPTX) give at the Piper Sandler Conference?

Leap Therapeutics will participate in a fireside chat format presentation at the conference.

Where is the Piper Sandler Healthcare Conference 2024 being held?

The Piper Sandler 36th Annual Healthcare Conference is being held in New York, NY.